Unless the context requires otherwise, capitalised terms in this announcement shall have the same meanings as those defined in the prospectus dated 29 June 2019 (the "**Prospectus**") issued by IVD Medical Holding Limited (the "**Company**").

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong). This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities of the Company. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described before deciding whether or not to invest in the Shares thereby being offered.

This announcement is not for release, publication or distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or elsewhere. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act or any state securities laws of the United States and may not be offered, sold, pledged or transferred within the United States or to, or for the account or benefit of U.S. persons, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirement of the U.S. Securities Act. There is not and it is not currently intended for there to be any public offering of the securities of the Company in the United States.



END OF STABILISATION PERIOD, STABILISATION ACTIONS AND LAPSE OF OVER-ALLOTMENT OPTION

This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong).

END OF STABILISATION PERIOD, STABILISATION ACTIONS AND LAPSE OF OVER-ALLOTMENT OPTION

The Company announces that the stabilisation period in connection with the Global Offering ended on 4 August 2019, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering.

Since no Share has been over-allocated under the International Offering, the Sole Global Coordinator (for itself and on behalf of the International Underwriters) did not exercise the Over-allotment Option, and no stabilisation action was carried out in relation to the Global Offering during the stabilisation period. The Over-allotment Option lapsed on 4 August 2019. Accordingly, no Share was or will be issued under the Over-allotment Option.

PUBLIC FLOAT

The Directors confirm that the Company continues to comply with the public float requirements under Rule 8.08(1)(a) of the Listing Rules whereby at least 25% of the Company's total number of issued Shares must at all times be held by the public.

By order of the Board **IVD Medical Holding Limited Ho Kuk Sing** *Chairman and Executive Director*

Hong Kong, 5 August 2019

As at the date of this announcement, the Board comprises Mr. Ho Kuk Sing, Mr. Leung King Sun and Mr. Lin Xianya, as executive Directors; Mr. Chen Xingang, Mr. Yang Zhaoxu and Mr. Chan Kwok King, Kingsley, as non-executive Directors; and Mr. Lau Siu Ki, Mr. Zhong Renqian and Mr. Leung Ka Sing, as independent non-executive Directors.